Remedium Bio

Remedium Bio Announces Strategic Collaboration with Lilly to Develop Gene Therapies for Obesity and Type 2 Diabetes remedium-bio.com/news.html #diabetes #obesity #biotechnology

🧬 Cell & Gene Therapies: High Risk or High Reward? Tufts just released one of the best datasets comparing CGT programs to traditional drugs. Across every phase, CGTs outperform. Some are 3.5x more likely to get approved. Here’s what the numbers tell us 🧵👇🏼

BOSTON, MA (May 12, 2025) -- Remedium Bio, Inc., a biotechnology company bringing genetic medicine to prevalent diseases, today announced the establishment of the Company’s research operations at Lilly Gateway Labs (LGL) in Boston. remedium-bio.com

Remedium receives investment from Healthspan Capital. @Healthspancap is an early-stage venture capital fund focused on longevity and regenerative medicine biotech start-ups, with the aim of extending healthy human lifespan. remedium-bio.com/news.html #genetherapy #venturecapital

Remedium Bio receives investment from LifeSpan Vision Ventures. LifeSpan Vision Ventures is a forward-thinking venture capital firm specializing in investments within the aging and longevity space. remedium-bio.com/news.html lifespanvisionventures.com #biotechnology #venturecapital

Remedium Bio to present at the Boston Biotech Investor Day, taking place Sep 10th in Cambridge, MA. Presented by LabCentral, Biolabs, and The Engine. #biotech #venturecapital #boston thebiocalendar.com/event/boston-b…

Remedium Bio announces publication of preclinical safety and efficacy data on RMD1501 - a treatment for cerebral #ischemia / #stroke, in the journal Restorative Neurology and Neuroscience. remedium-bio.com pubmed.ncbi.nlm.nih.gov/38363623

Remedium Bio nominated by Wharton Alumni Angels to present at the 2024 Alumni Startup Challenge. This year's event is taking place at the IndieBio NYC headquarters on Wed Jul 10. #genetherapy #biotechnology #venturecapital whartonalumniangels.com/alumni_startup…

Remedium Bio announces abstract acceptance for the 84th Scientific Sessions of the American Diabetes Association. This year's ADA is taking place Jun 21-24 in Orlando FL. professional.diabetes.org/scientific-ses… remedium-bio.com #genetherapy #biotechnology #diabetes #venturecapital

Remedium Bio announces the appointment of Dr. Kai Zou (Fellow of the American College of Sports Medicine, Assoc. Professor University of Massachusetts Boston) as the Endocrinology Scientific Advisor. remedium-bio.com/news.html #genetherapy #biotechnology #diabetes #obesity

Prometheus™ dose-adjustable gene therapy platfrom manuscript published in the journal Gene. authors.elsevier.com/c/1j1NG1L~GAwc… pubmed.ncbi.nlm.nih.gov/38663689 #genetherapy #biotechnology #diabetes

Check out our sponsored presentation with @RemediumB for Prometheus™ dose adjustable gene therapy platform technology at the 2024 American Society for Cell and Gene Therapy Conference! #ASGCT2024 #genetherapy #biotechnology #diabetes

Remedium to present the Prometheus™ dose-adjustable gene therapy platform at the 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, sponsored by @GenScript #genetherapy #biotechnology #diabetes annualmeeting.asgct.org

Remedium announces investment from Wharton Alumni Angels @wharangels “Our decision to invest in Remedium stems from the potential for their technology to significantly impact patients' lives by bringing the benefits of gene therapy to prevalent diseases" whartonalumniangels.com

Remedium Bio announces abstract acceptance for podium presentation at the 2024 OARSI World Congress. #genetherapy #biotechnology #venturecapital remedium-bio.com @OARSInews

Remedium Bio is pleased to welcome Ulu Ventures to the investor family. @uluventures Ulu Ventures is a 15-year-old investment fund focused on early-stage biotech, healthcare, and technology start-ups. #venturecapital #biotechnology #genetherapy uluventures.com

Remedium Bio abstract accepted for podium presentation at the 24th @ASGCTherapy annual meeting. This year's event is taking place May 7-11 in Baltimore. #genetherapy #biotechnology #diabetes asgct.org/24th-annual-me…

Remedium Bio receives investment from SeedFolio to advance lead asset, RMD1202, a gene therapy #GLP1 treatment for #obesity and #type2diabetes. seedfolio.vc Contact: Info@Remedium-Bio.com #genetherapy #biotechnology #venturecapital

Remedium Bio receives investment from SeedFolio to advance lead asset, RMD1202 - a GLP-1 gene therapy treatment for #obesity and type 2 diabetes, to first-in-human studies. seedfolio.vc Contact: info@remedium-bio.com #genetherapy #biotechnology #diabetes #GLP1

Remedium welcomes VitaDAO to the investor family. VitaDAO is a #biotechnology and longevity-focused early-stage investment firm comprised of over 10,000 members with representation from Pfizer Ventures and Appollo Health Ventures. VitaDAO.com Remedium-Bio.com